Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

Y Biologics at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

Y Biologics brings 2 presentations to SITC 2026 in Phoenix. Its program centres on immunocytokines that combine checkpoint blocking with a modified IL-2 in the same molecule. The candidates pair PD-1 with LAG-3 or VEGF targeting, aiming to overcome resistance to anti-PD-1 drugs and exploit VEGF-rich tumors.

Organization	SITC 2026 Attendance
YB Y Biologics Daejeon, South Korea
Biotech Develops antibody-based therapeutics, including immunocytokines for cancer.	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting Exhibition Halls 4-6 · Poster 811 New agents Poster Sat Nov 7 12:30–1:30pm 6:40–8:10pm AR170, a novel PD-1×VEGF×IL-2v tri-specific immunocytokine, exploits VEGF-enriched tumor microenvironments to elicit robust and durable antitumor immunity Exhibition Halls 4-6 · Poster 814 New agents

Organization

SITC 2026 Attendance

Y Biologics

Daejeon, South Korea

Biotech

Develops antibody-based therapeutics, including immunocytokines for cancer.

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

AR166, a novel tri-specific immunocytokine, overcomes anti-PD-1 resistance by delivering cis-acting IL-2v via dual PD-1 and LAG-3 targeting

Exhibition Halls 4-6 · Poster 811

New agents

Poster